MICROSCOPIC EVALUATION OF CRYSTALLIZATION DYNAMICS IN 0.25% LEVOBUPIVACAINE MIXED WITH COMMON REGIONAL ANAESTHESIA ADJUVANTS: AN IN VITRO COMPATIBILITY STUDY

Visolat SHARIPOVA, Shoira YULDOSHEVA, Ivan FOKIN

Turkish Journal of Anaesthesiology and Reanimation - 2026;54(5):416-424

Republican Scientific Centre of Emergency Medicine, Department of Anaesthesiology and Reanimation, Tashkent, Uzbekistan

 

Objective: To investigate the crystallization dynamics of 0.25% levobupivacaine when combined with common regional anaesthesia adjuvants. Methods: This in vitro study examined mixtures of 0.25% levobupivacaine with dexamethasone (20:1), 25% magnesium sulfate (20:1.5), dexmedetomidine (20:1), 8.4% sodium bicarbonate (10:1), and adrenaline (1:100,000). The study protocol was an in vitro investigation. Since no human or animal subjects were involved, the study was exempt from formal ethics committee approval. All mixtures were incubated at 37 dereceC and examined under light microscopy (40x magnification) immediately, at 15 minutes, and at 1 hour. Crystallization onset, crystal count, and crystal size were quantified. Results: Solutions containing sodium bicarbonate and dexamethasone demonstrated the earliest onset of crystallization. Sodium bicarbonate (10:1) produced immediate and massive precipitation. Levobupivacaine-dexamethasone mixtures showed progressive crystallization, with particle counts exceeding 100 per field for particles larger than 10 mum within 60 minutes. Adrenaline, magnesium sulfate, and dexmedetomidine showed significantly lower crystal densities than those of alkaline mixtures. Conclusion: Based on the present in vitro findings, adding either 8.4% sodium bicarbonate or dexamethasone to 0.25% levobupivacaine produced rapid, substantial crystallization, suggesting a physicochemical incompatibility under the tested conditions. These findings suggest that direct admixture of these agents with levobupivacaine in the same syringe should be approached with caution pending confirmation in clinical studies.